Search review questions

Failed apnea reduction · preterm infants with apnea

Positive‐pressure ventilation after institution of treatment · preterm infants with apnea

Supplemental oxygen at 36 weeks' postmenstrual age · preterm infants with apnea

Death or major neurodevelopmental disability at 18 to 24 months · preterm infants prior to extubation

Death at hospital discharge · preterm infants prior to extubation

Major neurodevelopmental disability at 18 to 24 months · preterm infants prior to extubation

Major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation

a) Cerebral palsy or gross motor disability · preterm infants prior to extubation

b) Developmental delay at 18 to 24 months · preterm infants prior to extubation

Failed extubation · preterm infants prior to extubation

Supplemental oxygen at 36 weeks' postmenstrual age · preterm infants prior to extubation

a) Cerebral palsy or gross motor disability · preterm infants at risk of or with apnea; preterm infants undergoing extubation

b) Developmental delay at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Any apneic episodes · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Failed apnea reduction · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Positive‐pressure ventilation after institution of treatment · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Supplemental oxygen at 36 weeks' postmenstrual age · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trials as absolute rates · neonates that require central line

Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) · neonates that require central line

Chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions (dermatitis) · neonates that require central line

All‐cause mortality throughout the hospital admission of the participant · neonates that require central line

Central line‐associated bloodstream infection (CLABSI) expressed using absolute rates of infants · neonates that require central line

The proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented · neonates that require central line

Premature central line removal, defined as number of central venous catheters (CVCs) removed in the trial as deemed by the author as the source of infection · neonates that require central line

Chemical burns or contact dermatitis, measured using a scoring system or by clinical judgement as described by the trial author during or after the application of antiseptic solutions (dermatitis) · neonates that require central line

All‐cause mortality throughout the hospital admission of the participant (mortality) · neonates that require central line

Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trial as absolute rates · neonates that require central line

Central‐line associated bloodstream infection (CLABSI) expressed by the authors of the individual trial as absolute rates · neonates that require central line

The proportion of infants or catheters with exit‐site infection, either microbiologically or clinically documented · neonates that require central line

All‐cause mortality prior to hospital discharge · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants at risk for apnea of prematurity

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants at risk for apnea of prematurity

Bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks' postmenstrual age · preterm infants at risk for apnea of prematurity

Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants at risk for apnea of prematurity

Duration of hospital stay (days) · preterm infants at risk for apnea of prematurity

Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants at risk for apnea of prematurity

All‐cause mortality prior to hospital discharge · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

Bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks' postmenstrual age · preterm infants with or at risk for apnea of prematurity

Side effects (tachycardia, agitation or feed intolerance) leading to a reduction in dose or withholding of caffeine: high‐loading and high‐maintenance dose standard‐loading and standard‐maintenance dose · preterm infants with or at risk for apnea of prematurity

Duration of hospital stay (days) · preterm infants with or at risk for apnea of prematurity

Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants with or at risk for apnea of prematurity

All‐cause mortality prior to hospital discharge · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity

Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity